Drug Trial Radar · NCT06476132
Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients
Last checked: Nov 20, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
234
Planned (sponsor's estimate)
Start
Mar 12, 2025
Primary completion
May 30, 2027
Study completion Jun 30, 2027
Sponsor
- Sponsor type
- NIH
- First posted
- Jun 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to see if taking the study drug, Belumosudil, for 52 weeks in addition to your usual care and medication, will prevent Chronic Lung Allograft Dysfunction (CLAD) in participants who have a lung biopsy that shows evidence of rejection or inflammation to the transplanted lung(s). For this study, biopsies that show evidence of Acute Rejection (AR), Lymphocytic Bronchiolitis (LB), Organizing Pneumonia (OP) or Acute Lung Injury (ALI) are referred to as "Qualifying Biopsies"; patients who had evidence of one or more of these conditions on a recent biopsy are eligible for enrollment in this study. Belumosudil is an investigational drug that blocks a molecule in the body that reduces inflammation and scarring and may play a role in the development and progression of CLAD. Belumosudil is a drug approved by the FDA to treat adults and children 12 years and older with chronic graft-versus-host disease (cGVHD), a condition with some similarities to CLAD. The primary objective it to determine the efficacy of treatment with Belumosudil + maintenance immunosuppression (IS) versus placebo + maintenance IS on preventing the subsequent development of probable or definite CLAD, lung retransplant, or death.
Conditions
- Lung Transplant
Interventions
BelumosudilDrug
Participants will receive Belumosudil 200 mg daily (increased to 200 mg twice daily in participants receiving concurrent strong CYP3A inducers or PPIs) + maintenance IS for a duration of one year from randomization.
Placebo for BelumosudilDrug
Participants will receive Placebo for Belumosudil 200 mg daily (increased to 200 mg twice daily in participants receiving concurrent strong CYP3A inducers or PPIs) + maintenance IS for a duration of one year from randomization.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time from randomization to the first occurrence of probable or definite CLAD (per ISHLT 2019 standard defined criteria), lung retransplant, or deathTime frame: From randomization until study completion - scheduled assessments: minimum of 1 year, maximum of 3 years
Locations
12 sites in 2 countries. Site status is shown where the registry gives one.
University of California, Los Angeles (Site #: 71123)
Los Angeles, California · Recruiting
Stanford University (Site #: 71141)
Palo Alto, California · Recruiting
Johns Hopkins (Site #: 71119)
Baltimore, Maryland · Recruiting
University of Minnesota (Site 71151)
Minneapolis, Minnesota · Recruiting
Washington University (Site #: 71157)
St Louis, Missouri · Recruiting
NYU Langone Health (Site #: 71177)
New York, New York · Recruiting
Duke University (Site #: 71139)
Durham, North Carolina · Recruiting
Cincinnati Children's Hospital Medical Center (Site #: 71017)
Cincinnati, Ohio · Recruiting
Cleveland Clinic (Site #: 71101)
Cleveland, Ohio · Recruiting
University of Pennsylvania (Site #: 71111)
Philadelphia, Pennsylvania · Recruiting
Vanderbilt University Medical Center (Site #: 71174)
Nashville, Tennessee · Recruiting
University Health Network/Toronto General Hospital (Site #: 71121)
Toronto, Ontario, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.